Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray.

Abstract

Mutations in the epidermal growth factor receptor (EGFR) make lung adenocarcinoma cells sensitive to EGFR tyrosine kinase inhibitors (TKIs). Long-term cancer therapy may cause the occurrence of acquired resistance to EGFR TKIs. Long non-coding RNAs (lncRNAs) play important roles in tumor formation, tumor metastasis and the development of EGFR-TKI resistance in lung cancer. To gain insight into the molecular mechanisms of EGFR-TKI resistance, we generated an EGFR-TKI-resistant HCC827-8-1 cell line and analyzed expression patterns by lncRNA microarray and compared it with its parental HCC827 cell line. A total of 1,476 lncRNA transcripts and 1,026 mRNA transcripts were dysregulated in the HCC827‑8-1 cells. The expression levels of 7 chosen lncRNAs were validated by real-time quantitative PCR. As indicated by functional analysis, several groups of lncRNAs may be involved in the bio-pathways associated with EGFR-TKI resistance through their cis- and/or trans‑regulation of protein-coding genes. Thus, lncRNAs may be used as novel candidate biomarkers and potential targets in EGFR-TKI therapy in the future.

• Authors: Ying Wu, Dan-Dan Yu, Yong Hu, Dali Yan, Xiu Chen, Hai-Xia Cao, Shao-Rong Yu, Zhuo Wang, Ji-Feng Feng
• Journal: Oncology reports (Oncol Rep) Vol. 35 Issue 6 Pg. 3371-86 (Jun 2016) ISSN: 1791-2431 [Electronic] Greece
• PMID: 27108960 (Publication Type: Journal Article)

Chemical References

• E2F1 Transcription Factor
• E2F1 protein, human
• MicroRNAs
• Protein Kinase Inhibitors
• RNA, Long Noncoding
• USF1 protein, human
• Upstream Stimulatory Factors
• EGFR protein, human
• ErbB Receptors

Topics

• Adenocarcinoma (drug therapy, genetics)
• Adenocarcinoma of Lung
• Cell Line, Tumor
• Drug Resistance, Neoplasm
• E2F1 Transcription Factor (physiology)
• ErbB Receptors (antagonists & inhibitors)
• Humans
• Lung Neoplasms (drug therapy, genetics)
• MicroRNAs (analysis)
• Oligonucleotide Array Sequence Analysis
• Protein Kinase Inhibitors (therapeutic use)
• RNA, Long Noncoding (analysis)
• Real-Time Polymerase Chain Reaction
• Upstream Stimulatory Factors (physiology)